EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes

Jungyeon Moon iD, Aya F Ozaki iD, Alice Chong, Maneesh Sud, Jiming Fang, Peter C Austin, Dennis T Ko, Cynthia A Jackevicius iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Jungyeon Moon und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Western University of Health Sciences, Pomona, California, USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Atrial Fibrillation, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

P2Y12 inhibitors (P2Y12i) reduce cardiac events after acute coronary syndromes (ACS). However, suboptimal P2Y12i adherence persists. We aimed to examine P2Y12i non‐adherence using group‐based trajectory methods and to identify adherence predictors.

Methods

We conducted a population‐based, retrospective cohort study using administrative data in Ontario, Canada of patients ≥65 years admitted for ACS between April 2014 and March 2018 with a P2Y12i dispensed within 7 days of discharge. We used group‐based trajectory models to characterize longitudinal 1‐year adherence patterns. Predictors associated with each adherence trajectory were identified by multinomial logistic regression.

Results

We included 11 917 patients using clopidogrel and 9763 using ticagrelor, aged [mean ± SD]: 77.33 ± 8.31/73.59 ± 6.79 years; men: 56.2%/65.4%, respectively. We identified 3 longitudinal adherence trajectories, that differed by agent: 75% of clopidogrel and 68% of ticagrelor patients showed a consistently adherent trajectory, while 13%/17% were gradually, and 12%/15% were rapidly non‐adherent, respectively ( p < 0.001). Differing baseline characteristics in each cohort were associated with observed adherence trajectories. Concomitant atrial fibrillation and prior bleeding history were associated with non‐adherence among clopidogrel users. Among ticagrelor users, women and older persons were more likely to be rapidly non‐adherent, adherence declining steeply starting 1 month post‐ACS.

Conclusions

We identified distinct adherence trajectories for clopidogrel and ticagrelor post‐ACS, with 3 out of 4 clopidogrel patients but only 2 out of 3 ticagrelor patients in the consistently adherent trajectory. Intensive interventions targeted to the period of steep adherence decline post‐ACS, particularly for women and older persons initiating ticagrelor, and patients with atrial fibrillation on clopidogrel should be considered and investigated further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAtrial FibrillationPercutaneous Coronary InterventionMaleHumansFemaleAgedAged, 80 and overClopidogrelPlatelet Aggregation InhibitorsTicagrelorRetrospective StudiesOntarioPurinergic P2Y Receptor AntagonistsTreatment Outcome

Stichwörter der Autor:innen

P2Y12 inhibitoracute coronary syndromesadherenceantiplateletsgroup-based trajectory models

Substanzen

ClopidogrelPlatelet Aggregation InhibitorsTicagrelorPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • College of Pharmacy, Western University of Health Sciences, Pomona, California, USA.
  • School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, California, USA.
  • ICES, Toronto, Canada.
  • University of Toronto, Toronto, Ontario, Canada.
  • Schulich Heart Centre Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.

ORCID-Profile: Jungyeon Moon, Aya F Ozaki, Cynthia A Jackevicius

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Moon, J., Ozaki, A. F., Chong, A., Sud, M., Fang, J., Austin, P. C., Ko, D. T., & Jackevicius, C. A. (2024). Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5704

Vancouver

Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, et al. Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5704

BibTeX
@article{Moon2024,
  author = {Moon, Jungyeon and Ozaki, Aya F and Chong, Alice and Sud, Maneesh and Fang, Jiming and Austin, Peter C and Ko, Dennis T and Jackevicius, Cynthia A},
  title = {Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5704}
}
Kostenlos starten →